(VIANEWS) – Shares of TARGOVAX (Oslo Børs Benchmark Index_GI: TRVX.OL) slid by a staggering 27.08% in 21 sessions from kr0.96 to kr0.70 at 19:39 EST on Thursday, after four consecutive sessions in a row of losses. Oslo Børs Benchmark Index_GI is dropping 0.02% to kr1,160.00, after five consecutive sessions in a row of losses.
TARGOVAX’s last close was kr0.72, 63.11% below its 52-week high of kr1.96.
About TARGOVAX
Targovax ASA, a clinical stage immuno-oncology company, engages in the development of immune activators to target hard-to-treat solid tumors. Its lead product candidate is ONCOS-102, which is in Phase I/II clinical trials for the treatment of mesothelioma, melanoma, and colorectal cancer. The company is also developing neoantigen vaccines targeting mutant KRAS cancers. In addition, it is developing ONCOS-211 for next generation ONCOS viruses. The company has collaboration agreements with Cancer Research Institute and Ludwig Cancer Research to develop ONCOS-102 for colorectal cancer with peritoneal carcinomatosis; Valo Therapeutics to develop mutant RAS neoantigen coating of ONCOS viruses using PeptiCRAd technology; and Papyrus Therapeutics to develop novel ONCOS viruses with Receptor Tyrosine Kinase inhibitor functionality. Targovax ASA was incorporated in 2010 and is based in Lysaker, Norway.
Earnings Per Share
As for profitability, TARGOVAX has a trailing twelve months EPS of kr-1.402.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -32.59%.
Volatility
TARGOVAX’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.04%, a negative 2.22%, and a positive 2.99%.
TARGOVAX’s highest amplitude of average volatility was 2.04% (last week), 4.63% (last month), and 2.99% (last quarter).
More news about TARGOVAX (TRVX.OL).
